Browsing by Author "Buka D."
Now showing 1 - 7 of 7
Results Per Page
Sort Options
- ItemAssociation of the combined parameters including the frequency of primary cilia, CD8 tumor infiltrating lymphocytes and PD-1 expression with the outcome in intestinal cancer(Zerbinis Medical Publications, 2017-01-01) Dvořák Josef; Nikolov DH; Dušek Ladislav; Filipová Alžběta; Richter Igor; Buka D.; Ryska Aleš; Mokrý Jaroslav; Filip Stanislav; Melichar Bohuslav; Buchler Tomáš; Abrahámová Jitka
- ItemThe changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma(Termedia Sp. z.o.o., 2017-01-01) Buka D.; Dvořák Josef; Sitorová Veronika; Sirák Igor; Vobořil René; Melichar Bohuslav; Richter IgorAim of the study: The aim was to examine the effects of neoadjuvant chemoradiotherapy on VEGF expression in patients with locally advanced rectal cancer. Materials and methods: A total of 53 patients with locally advanced rectal cancer were retrospectively studied. Neoadjuvant treatment comprised external beam radiation (50.4 Gy/28 fractions) with continuous infusion of 5-fluorouracil. Four to 6 weeks after the chemoradiotherapy, the patients underwent surgical resection. Immunohistochemistry was performed to assess VEGF expression in the pretreatment biopsies and in resected specimens. Results: Resection with microscopic residual tumour (R1) was performed in two patients while in the remaining 51 patients radical resection with microscopically negative margins (R0) was possible. Downstaging after preoperative chemoradiotherapy was observed in 34 patients (64%). After chemoradiotherapy 24 patients (45%) had decreased VEGF expression, in 20 patients (38%) there was no change, and in two patients it was not possible to assess the dynamics of VEGF expression due to pathologic complete response after chemoradiotherapy. The five-year overall survival (OS) rate was 56% (95% CI: 43–70%). Although the median OS was 2.5 times shorter in patients who experienced decreased VEGF expression during therapy, this difference did not reach statistical significance. VEGF expression was not significant in Cox regression analysis or log-rank test. VEGF expression decreased after neoadjuvant chemoradiotherapy in most patients with rectal adenocarcinoma examined. This decrease was associated with a trend of inferior prognosis. Conclusions: VEGF expression decreased after neoadjuvant chemoradiotherapy in most patients examined. This decrease was associated with a trend of inferior prognosis.
- ItemCobimetinib-progress in the treatment of melanoma(Svoboda, 2017-01-01) Dvořák Josef; Richter Igor; Buka D.; Abrahámová Jitka
- ItemCurrent treatment options for metastatic castar-resistant prostate cancer(Current Media s.r.o, 2018-01-01) Rozsypalová Aneta; Dvořák Josef; Richter Igor; Buka D.; Grimová Jana; Matoušková Michaela
- ItemInterakce mezi anti-VEGF léčbou a protinádorovou imunitou jako potenciální léčebná strategie kolorektálního karcinomu(2019-01-01) Buka D.; Dvořák Josef; Richter Igor; Škrobánek Pavel; Buchler Tomáš; Melichar Bohuslav
- ItemPrincipal Relationship of Primary Lines, Pd-1 And Cd8 Tumor Influencing Lymphocytes At the Adenokarcinom of the Tensile Wood And Colorate(2017-01-01) Dvořák Josef; Hadži Nikolov D.; Dušek L.; Filipová A.; Richter Igor; Buka D.; Ryška A.; Melichar Bohuslav; Buchler Tomáš; Abrahámová Jitka
- ItemSimulations of centriole of polarized centrozome as a monopole antenna in immune and viral synapses(2018-01-01) Dvořák Josef; Melichar Bohuslav; Filipová A.; Grimová Jana; Rozsypalová Aneta; Buka D.; Vobořil René; Zapletal R.; Buchler Tomáš; Richter Igor